Artivion (NYSE:AORT) Stock Breaks Above Fifty Day Moving Average - Should You Sell?

Key Points

• Artivion shares moved above their 50-day moving average, trading at $23.77 versus the average of $23.72; the stock remains below its 200-day average of $29.27.
• Analysts have a “Moderate Buy” consensus, with an average price target of $42.86. Seven analysts rate the stock Buy and one rates it Sell.
• In its latest reported quarter, Artivion posted EPS of $0.13 and revenue of $125.76 million, beating analysts’ revenue estimate of $119.99 million. Insiders sold 90,460 shares worth about $2.56 million over the past 90 days.

Artivion, Inc. (NYSE:AORT - Get Free Report) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $23.72 and traded as high as $23.94. Artivion shares last traded at $23.77, with a volume of 645,726 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AORT. Canaccord Genuity Group raised their price target on shares of Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, August 18th. Needham & Company LLC reaffirmed a "buy" rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Citigroup reaffirmed a "market outperform" rating on shares of Artivion in a research report on Tuesday, July 21st. Weiss Ratings downgraded Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Jefferies Financial Group began coverage on shares of Artivion in a research report on Tuesday, October 20th. They issued a "buy" rating and a $31.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.86.

Artivion Trading Up 0.8%

The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a 50-day simple moving average of $23.72 and a 200 day simple moving average of $29.27. The company has a market capitalization of $1.16 billion, a P/E ratio of -339.52 and a beta of 1.31.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The company had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Sell-side analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Insider Activity at Artivion

In other Artivion news, CEO James Mackin sold 70,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company's stock, valued at $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jean Holloway sold 977 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares of the company's stock, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 90,460 shares of company stock worth $2,557,366 in the last ninety days. 6.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Artivion during the second quarter valued at approximately $149,965,000. Wellington Management Group LLP lifted its position in Artivion by 9.0% in the second quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company's stock worth $28,318,000 after purchasing an additional 103,592 shares during the period. Dimensional Fund Advisors LP lifted its position in Artivion by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,027,575 shares of the company's stock worth $37,626,000 after purchasing an additional 46,738 shares during the period. Bank of America Corp DE lifted its position in Artivion by 0.8% in the first quarter. Bank of America Corp DE now owns 522,515 shares of the company's stock worth $19,135,000 after purchasing an additional 3,980 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Artivion by 8.7% during the first quarter. Principal Financial Group Inc. now owns 261,370 shares of the company's stock worth $9,571,000 after buying an additional 20,921 shares in the last quarter. Institutional investors own 86.37% of the company's stock.

About Artivion

Artivion, Inc NYSE: AORT is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company's products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.